Wilmanski-Gibbons

Gut Microbiome Composition Predictive of Patient Response to Statins

New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.

Gut Microbiome Composition Predictive of Patient Response to Statins
Gut Microbiome Composition Predictive of Patient Response to Statins
screenshot of video for Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis

Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis

Researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. They also found that mild cases of COVID-19, not just severe cases, are associated with long COVID. Their findings were published by the journal Cell.

Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis
Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis
screenshot of video for Maternal COVID-19 Infection Increases Risks of Preterm Birth, Low Birth Weight and Stillbirth

Maternal COVID-19 Infection Increases Risks of Preterm Birth, Low Birth Weight and Stillbirth

An ISB-led study examined the electronic health records of more than 18,000 people with SARS-CoV-2 tests during pregnancy, and found that those who contracted COVID-19 while pregnant were more likely to have poor birth outcomes including preterm birth, small for gestational age, low birth weight, and stillbirth. 

Maternal COVID-19 Infection Increases Risks of Preterm Birth, Low Birth Weight and Stillbirth
Maternal COVID-19 Infection Increases Risks of Preterm Birth, Low Birth Weight and Stillbirth
screenshot of video for Fireside Chat with NIH Director Francis Collins and ISB Co-founder Dr. Lee Hood

Fireside Chat with NIH Director Francis Collins and ISB Co-founder Dr. Lee Hood 

ISB Co-founder Dr. Lee Hood hosted a fireside chat with NIH Director Dr. Francis Collins. The renowned scientists talked about their early careers and long friendship, the challenge of COVID-19, the preceding scientific work that led to the fast development of COVID vaccines, and much more. 

Fireside Chat with NIH Director Francis Collins and ISB Co-founder Dr. Lee Hood 
Fireside Chat with NIH Director Francis Collins and ISB Co-founder Dr. Lee Hood 
Claire Reid / Los Angeles Times; Getty Images, Unsplash

Dr. Lee Hood Writes ‘Second Opinion’ Columns for Los Angeles Times

ISB Co-founder Dr. Lee Hood is credited with coining the term “systems biology” and has been a longtime advocate of P4 medicine. Now, Hood has been selected by the Los Angeles Times to share his insights in a new weekly op-ed column, called Second Opinion.

Dr. Lee Hood Writes ‘Second Opinion’ Columns for Los Angeles Times
Dr. Lee Hood Writes ‘Second Opinion’ Columns for Los Angeles Times
screenshot of video for Select Coaching for Cognition in Alzheimer’s (COCOA) Clinical Trial Nearly Complete Coaching for Cognition in Alzheimer’s (COCOA) Clinical Trial Nearly Complete

Coaching for Cognition in Alzheimer’s (COCOA) Clinical Trial Nearly Complete

The multi-year Coaching for Cognition in Alzheimer’s (COCOA) clinical trial is nearly complete. The trial examined diet, exercise and cognitive training as possible non-pharmacological interventions to Alzheimer’s, with some trial members receiving telephonic coaching centered on stress, diet and exercise, as well as brain training focusing on brain speed and attention.

Coaching for Cognition in Alzheimer’s (COCOA) Clinical Trial Nearly Complete
Coaching for Cognition in Alzheimer’s (COCOA) Clinical Trial Nearly Complete
1 2 3 4 5 7